Trial Profile

A study of SSS67

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SSS 67 (Primary)
Indications Obesity
Focus Adverse reactions

Most Recent Events

14 Apr 2026 New trial record
13 Mar 2026 According to 3SBio media release, company has received IND (Investigational New Drug) approval from the U.S. Food and Drug Administration for its independently developed SSS67. marking the official entry of this innovative bispecific antibody drug targeting ActRIIA/ActRIIB into the clinical stage.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com